ContraFect (NASDAQ:CFRX) Downgraded to Sell at StockNews.com

StockNews.com lowered shares of ContraFect (NASDAQ:CFRX – Get Rating) from a hold rating to a sell rating in a report released on Thursday.

Separately, Maxim Group raised ContraFect from a hold rating to a buy rating and set a $3.00 price target on the stock in a research note on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ContraFect presently has a consensus rating of Hold and an average target price of $180.75.

ContraFect Trading Down 5.2 %

Shares of NASDAQ CFRX opened at $1.47 on Thursday. The stock has a market cap of $2.31 million, a price-to-earnings ratio of -0.02 and a beta of 0.44. ContraFect has a 1-year low of $0.90 and a 1-year high of $363.20. The stock’s 50-day moving average is $1.67 and its 200 day moving average is $5.45.

ContraFect (NASDAQ:CFRX – Get Rating) last announced its quarterly earnings results on Friday, March 31st. The biotechnology company reported ($16.14) EPS for the quarter. On average, analysts forecast that ContraFect will post -15.39 EPS for the current fiscal year.

Hedge Funds Weigh In On ContraFect

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of ContraFect by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock valued at $5,664,000 after buying an additional 11,064 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of ContraFect by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock valued at $1,486,000 after buying an additional 4,948 shares during the period. State Street Corp increased its stake in shares of ContraFect by 33.5% during the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock valued at $474,000 after buying an additional 32,563 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ContraFect by 62.9% during the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 43,564 shares during the period. Finally, Armistice Capital LLC purchased a new position in shares of ContraFect during the fourth quarter valued at approximately $393,000. 27.34% of the stock is owned by hedge funds and other institutional investors.

About ContraFect

(Get Rating)

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.